Prevalence and modifiable risk factors of degenerative valvular heart disease among elderly population in southern China

Shang-Fei HE; Jun-Rong JIANG; Fang-Zhou LIU; Hong-Tao LIAO; Yu-Mei XUE; Mu-Rui ZHENG; Huo-Xing LI; Hai DENG; Shu-Lin WU

doi:10.11909/j.issn.1671-5411.2021.07.003

Volume 18 Issue 7

Jul. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Geriatric Cardiology > 2021 > 18(7): 523-533

Please cite this article as: HE SF, JIANG JR, LIU FZ, LIAO HT, XUE YM, ZHENG MR, LI HX, DENG H, WU SL. Prevalence and modifiable risk factors of degenerative valvular heart disease among elderly population in southern China. J Geriatr Cardiol 2021; 18(7): 523−533. DOI: 10.11909/j.issn.1671-5411.2021.07.003

Citation:

Please cite this article as: HE SF, JIANG JR, LIU FZ, LIAO HT, XUE YM, ZHENG MR, LI HX, DENG H, WU SL. Prevalence and modifiable risk factors of degenerative valvular heart disease among elderly population in southern China. J Geriatr Cardiol 2021; 18(7): 523−533. DOI: 10.11909/j.issn.1671-5411.2021.07.003

Citation:

PDF( 477 KB)

Prevalence and modifiable risk factors of degenerative valvular heart disease among elderly population in southern China

doi: 10.11909/j.issn.1671-5411.2021.07.003

1.
South China University of Technology School of Medicine, Guangzhou, China
2.
Department of Cardiology, Guangdong Provincial People’s Hospital, Guangzhou, China
3.
Guangzhou Center for Disease Control and Prevention, Guangzhou, China
4.
Qinghai Province Cardio Cerebrovascular Disease Specialist Hospital, Xining, China

More Information

Corresponding author: doctordh2020@163.com; wushulincn@126.com
Publish Date: 2021-07-28

Abstract

Abstract

Objective To investigate the prevalence and modifiable risk factors of degenerative valvular heart disease (DVHD) among elderly population in southern China. Methods A stratified multistage sampling method was used to recruit subjects. The contents of the survey included the questionnaire, laboratory examination, echocardiography, and other auxiliary examinations. The possible risk factors of DVHD were analyzed by logistic regression analysis. Results A total of 3538 subjects ≥ 65 years of age were enrolled. One thousand three hundred and seven subjects (36.9%) were diagnosed with DVHD. Degenerative was the most common etiology of VHD. Prevalence of DVHD increased with advancing age. The prevalence of DVHD differed by living region (χ² = 45.594, P < 0.001), educational level (χ² = 50.557, P < 0.001), and occupation (χ² = 36.961, P < 0.001). Risk factors associated with DVHD included age (two-fold increased risk for each 10-year increase in age), elevated level C-reactive protein (OR = 1.346, 95% CI: 1.100−1.646), elevated level low density lipoprotein (OR = 1.243, 95% CI: 1.064−1.451), coronary artery disease (OR = 1.651, 95% CI: 1.085−2.513), smoking (OR = 1.341, 95% CI: 1.132−1.589), and hypertension (OR = 1.414, 95% CI: 1.221−1.638). Other significant risk factors included reduced or elevated level red blood cell (OR = 1.347, 95% CI: 1.031−1.761; OR = 1.599, 95% CI: 1.097−2.331; respectively), elevated level platelets (OR = 1.891, 95% CI: 1.118−3.198), elevated level uric acid (OR = 1.282, 95% CI: 1.112−1.479), and stroke (OR: 1.738, 95% CI = 1.085−2.513). Conclusions The survey characterized the baseline conditions of DVHD cohort of elderly population in Guangzhou city. The established and emerging risk factors for DVHD may represent challenges and opportunities for therapy.

FullText(HTML)

References(22)

References

[1]	Liu F, Xue Y, Liao H, et al. Five-year epidemiological survey of valvular heart disease: changes in morbidity, etiological spectrum and management in a cardiovascular center of Southern China. J Thorac Dis 2014; 6: 1724−1730.
[2]	Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on valvular heart disease. Eur Heart J 2003; 24: 1231−1243. doi: 10.1016/S0195-668X(03)00201-X
[3]	Marijon E, Ou P, Celermajer DS, et al. Prevalence of rheumatic heart disease detected by echocardiographic screening. N Engl J Med 2007; 357: 470−476. doi: 10.1056/NEJMoa065085
[4]	Hu P, Liu XB, Liang J, et al. A hospital-based survey of patients with severe valvular heart disease in China. Int J Cardiol 2017; 231: 244−247. doi: 10.1016/j.ijcard.2016.11.301
[5]	Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997; 29: 630−634.
[6]	Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015; 16: 233−270. doi: 10.1093/ehjci/jev014
[7]	Wasilewski J, Mirota K, Wilczek K, et al. Calcific aortic valve damage as a risk factor for cardiovascular events. Pol J Radiol 2012; 77: 30−34. doi: 10.12659/PJR.883626
[8]	Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: e57−e185. doi: 10.1016/j.jacc.2014.02.536
[9]	Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: 2440−2492. doi: 10.1161/CIR.0000000000000029
[10]	Marmelo FC, Mateus SM, Pereira AJ. Association of aortic valve sclerosis with previous coronary artery disease and risk factors. Arq Bras Cardiol 2014; 103: 398−402.
[11]	Sliwa K, Carrington M, Mayosi BM, et al. Incidence and characteristics of newly diagnosed rheumatic heart disease in urban African adults: insights from the heart of Soweto study. Eur Heart J 2010; 31: 719−727. doi: 10.1093/eurheartj/ehp530
[12]	Demirbağ R, Sade LE, Aydın M, et al. The Turkish registry of heart valve disease. Turk Kardiyol Dern Ars 2013; 41: 1−10. doi: 10.5543/tkda.2013.71430
[13]	Iung B, Vahanian A. Epidemiology of acquired valvular heart disease. Can J Cardiol 2014; 30: 962−970. doi: 10.1016/j.cjca.2014.03.022
[14]	Pasca I, Dang P, Tyagi G, Pai RG. Survival in patients with degenerative mitral stenosis: results from a large retrospective cohort study. J Am Soc Echocardiogr 2016; 29: 461−469. doi: 10.1016/j.echo.2015.12.012
[15]	Chen HY, Engert JC, Thanassoulis G. Risk factors for valvular calcification. Curr Opin Endocrinol Diabetes Obes 2019; 26: 96−102. doi: 10.1097/MED.0000000000000471
[16]	Lindroos M, Kupari M, Valvanne J, et al. Factors associated with calcific aortic valve degeneration in the elderly. Eur Heart J 1994; 15: 865−870. doi: 10.1093/oxfordjournals.eurheartj.a060602
[17]	Aronow WS, Schwartz KS, Koenigsberg M. Correlation of serum lipids, calcium, and phosphorus, diabetes mellitus and history of systemic hypertension with presence or absence of calcified or thickened aortic cusps or root in elderly patients. Am J Cardiol 1987; 59: 998−999. doi: 10.1016/0002-9149(87)91144-1
[18]	Hsu SY, Hsieh IC, Chang SH, et al. Aortic valve sclerosis is an echocardiographic indicator of significant coronary disease in patients undergoing diagnostic coronary angiography. Int J Clin Pract 2005; 59: 72−77. doi: 10.1111/j.1368-504X.2005.00342.x
[19]	Bouchareb R, Boulanger MC, Tastet L, et al. Activated platelets promote an osteogenic programme and the progression of calcific aortic valve stenosis. Eur Heart J 2019; 40: 1362−1373. doi: 10.1093/eurheartj/ehy696
[20]	Uchida S, Kumagai T, Chang WX, et al. Time to target uric acid to retard chronic kidney disease progression. Contrib Nephrol 2018; 192: 56−68.
[21]	Fox CS, Larson MG, Vasan RS, et al. Cross-sectional association of kidney function with valvular and annular calcification: the Framingham heart study. J Am Soc Nephrol 2006; 17: 521−527. doi: 10.1681/ASN.2005060627
[22]	Mehta T, Nuccio E, McFann K, et al. Association of uric acid with vascular stiffness in the framingham heart study. Am J Hypertens 2015; 28: 877−883. doi: 10.1093/ajh/hpu253